Bibliographic Details
| Title: |
1180TiP Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanoma. |
| Authors: |
Schadendorf, D.1 (AUTHOR), Dummer, R.2 (AUTHOR), Ribas, A.3 (AUTHOR), Robert, C.4 (AUTHOR), Sullivan, R.J.5 (AUTHOR), King, A.6 (AUTHOR), Polli, A.7 (AUTHOR), di Pietro, A.8 (AUTHOR), Ascierto, P.A.9 (AUTHOR) |
| Source: |
Annals of Oncology. 2023 Supplement 2, Vol. 34, pS700-S700. 1p. |
| Database: |
Academic Search Ultimate |
